Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Actinogen Medical (ACW)

Latest price

AUD0.05

— 0.00 (0.00)

As at 07/06/2023

Market capitalisation: AUD91m

19.10.22

Actinogen Medical — Cognitive enhancer targeting key diseases

18.10.22

Actinogen Medical — Cognitive enhancer targeting key diseases

18.10.22

Actinogen Medical — Cognitive enhancer targeting key diseases

See more
content on

Actinogen Medical

AFT Pharmaceuticals (AFT)

Latest price

NZD3.90

▾ 0.07 (1.83)

As at 07/06/2023

Market capitalisation: NZD409m

Healthcare

07.09.22

AFT Pharmaceuticals — Further studies for Maxigesic IV’s US nod

Plate of pills. Background or texture

Healthcare

02.09.22

AFT Pharmaceuticals — Collaboration for developing birthmark medicine

Healthcare

28.07.22

AFT Pharmaceuticals — Pascomer falls short of FDA mandated threshold

See more
content on

AFT Pharmaceuticals

Basilea Pharmaceutica (BSLN)

Latest price

CHF44.65

▾ −0.55 (−1.22)

As at 07/06/2023

Market capitalisation: CHF585m

25.10.22

Basilea Pharmaceutica — New supportive data from ERADICATE

Healthcare

23.09.22

Basilea Pharmaceutica — Oncology asset sales continue

Healthcare

09.09.22

Basilea Pharmaceutica — Strategic streamlining – sale of oncology assets

See more
content on

Basilea Pharmaceutica

Biodexa Pharmaceuticals (BDRX)

Latest price

US$0.95

▾ −0.25 (−20.83)

As at 07/06/2023

Market capitalisation: US$2m

Healthcare

21.06.22

Midatech Pharma — MTX110 receives ODD from the EMA for gliomas

Healthcare

13.06.22

Midatech Pharma — Interim DIPG data to be presented at ISPNO

Healthcare

06.06.22

Midatech Pharma — MTX110’s path to market fast-tracked in rGBM

See more
content on

Biodexa Pharmaceuticals

Cantargia (CANTA)

Latest price

SEK4.61

▾ −0.07 (−1.50)

As at 07/06/2023

Market capitalisation: SEK770m

14.10.22

Cantargia — Recruitment milestone achieved

Healthcare

22.09.22

Cantargia — First patient treated under CIRIFOUR trial

Healthcare

31.08.22

Cantargia — A positive H122 supports clinical activity

See more
content on

Chimeric Therapeutics (CHM)

Latest price

AUD0.04

— 0.00 (0.00)

As at 07/06/2023

Market capitalisation: AUD31m

Healthcare

06.12.21

Chimeric Therapeutics — Acquiring an exciting new NK cell technology

Healthcare

29.07.21

Chimeric Therapeutics — Acquiring a promising first-in-class CAR T asset

Healthcare

19.01.21

Chimeric Therapeutics — Scorpion venom CAR-T stalking GBM

See more
content on

Chimeric Therapeutics

Chosa (CHOSA)

Latest price

SEK1.30

▾ −0.23 (−15.03)

As at 07/06/2023

Market capitalisation: SEK96m

Edison Oncology part 3

Healthcare

28.02.22

RhoVac — On the home straight

Edison Oncology part 3

Healthcare

14.10.21

RhoVac — Phase IIb BRaVac study results in H122

Edison Oncology part 3

Healthcare

26.04.21

RhoVac — COVID-19 vaccines versus RV001

See more
content on

Context Therapeutics (CNTX)

Latest price

USD1.40

▾ 0.11 (8.53)

As at 07/06/2023

Market capitalisation: USD22m

Healthcare

28.09.22

Context Therapeutics — Cash runway extended to Q124

Healthcare

12.08.22

Context Therapeutics — Anticipating a catalyst rich Q422

mockup-graphics--msTEzGwKJs-unsplash

Healthcare

02.08.22

Context Therapeutics — Promising combination therapy for ONA-XR

See more
content on

Context Therapeutics

Creo Medical (CREO)

Latest price

GBP0.23

▾ −1.25 (−5.10)

As at 07/06/2023

Market capitalisation: GBP82m

Healthcare

14.09.22

Creo Medical — Building momentum in 2022

Healthcare

04.08.22

Creo Medical — Continued growth momentum in H122

Healthcare

25.05.22

Creo Medical — Solid FY21 followed by robotics deal with Intuitive

See more
content on

e-therapeutics (ETX)

Latest price

GBP0.18

▾ −0.05 (−0.28)

As at 07/06/2023

Market capitalisation: GBP103m

Ergomed (ERGO)

Latest price

GBP9.88

— 0.00 (0.00)

As at 07/06/2023

Market capitalisation: GBP502m

Healthcare

30.09.22

Ergomed — Poised for a strong FY22

Healthcare

27.07.22

Ergomed — Sustained growth momentum in H122

Healthcare

27.04.22

Ergomed — Healthy fundamentals for 2022

See more
content on

Immix Biopharma (IMMX)

Latest price

USD1.97

▾ −0.07 (−3.43)

As at 07/06/2023

Market capitalisation: USD30m

16.09.22

Immix Biopharma — Fresh faces with a unique tissue-targeting therapy

See more
content on

Immix Biopharma

Incannex Healthcare (IXHL)

Latest price

USD1.96

▾ 0.03 (1.29)

As at 07/06/2023

Market capitalisation: USD124m

Healthcare

23.09.22

Incannex Healthcare — Targeting FDA studies in FY23

Healthcare

30.08.22

Incannex Healthcare — Addressing unmet needs via alternative approach

Healthcare

08.08.22

Incannex Healthcare — APIRx acquisition to bolster portfolio

See more
content on

Incannex Healthcare

IRLAB Therapeutics (IRLABA)

Latest price

SEK8.42

▾ 0.08 (0.96)

As at 07/06/2023

Market capitalisation: SEK436m

Healthcare

13.09.22

IRLAB Therapeutics — Phase IIb recruitment complete

Healthcare

08.09.22

IRLAB Therapeutics — Ipsen confirms commitment with clinical studies

Healthcare

25.08.22

IRLAB Therapeutics — All steady as key catalyst approaches

See more
content on

IRLAB Therapeutics

Kazia Therapeutics (KZIA)

Latest price

USD1.28

▾ 0.02 (1.59)

As at 07/06/2023

Market capitalisation: USD22m

10.10.22

Kazia Therapeutics — PNOC022 trial expanded

Healthcare

05.09.22

Kazia Therapeutics — Doubling down on clinical development

Healthcare

08.08.22

Kazia Therapeutics — Ambiguity in GBM but pipeline still busy

See more
content on

Kazia Therapeutics

Kinarus Therapeutics (KNRS)

Latest price

CHF0.01

— 0.00 (−8.33)

As at 07/06/2023

Market capitalisation: CHF15m

Healthcare

05.09.22

Kinarus Therapeutics — H122 results reflect continued progress

Healthcare

31.08.22

Kinarus — Phase II COVID-19 outpatient study underway

Healthcare

24.08.22

Kinarus — A unique combination targeting unmet needs

See more
content on

Kinarus Therapeutics

Load more

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free